Mesoblast extends payer coverage for ryoncil® to over 100 million us lives

New york, april 16, 2025 (globe newswire) -- mesoblast (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for ryoncil® (remestemcel-l), the first mesenchymal stromal cell (msc) therapy approved by u.s. food and drug administration (fda) for any indication, to 104 million us lives insured by government and commercial payers.
MESO Ratings Summary
MESO Quant Ranking